Eprosartan: An angiotensin-II receptor antagonist for the management of hypertension

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Eprosartan is a competitive angiotensin-II receptor antagonist with a high affinity for the angiotensin-II subtype 1 receptor. The drug has an elimination half-life of approximately 5 to 9 hours and duration of antihypertensive effect of up to 24 hours. The antihypertensive efficacy of eprosartan has been examined in a number of placebo-controlled, dose-finding, and comparative trials. Results of these clinical trials have consistently shown statistically significant differences in antihypertensive efficacy favoring eprosartan doses of 400 mg or greater per day over placebo. Eprosartan was also shown to be at least as effective as enalapril at lowering blood pressure in patients with mild to severe hypertension. The frequency of adverse events observed with eprosartan has been similar to that seen with placebo. In addition, there are no clinically significant drug interactions associated with eprosartan. Given the excellent tolerability and drug-interaction profiles of eprosartan, the use of this agent may help to improve patient compliance to a drug regimen. In addition, eprosartan may be particularly advantageous when used as a part of combination therapy for the management of hypertension.

Original languageEnglish (US)
Pages (from-to)54-59
Number of pages6
JournalHeart Disease
Volume4
Issue number1
StatePublished - 2002

Fingerprint

Angiotensin Receptor Antagonists
Hypertension
Antihypertensive Agents
Placebos
Drug Interactions
Enalapril
eprosartan
Patient Compliance
Angiotensin II
Pharmaceutical Preparations
Half-Life
Clinical Trials
Blood Pressure

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Eprosartan : An angiotensin-II receptor antagonist for the management of hypertension. / Cheng-Lai, Angela.

In: Heart Disease, Vol. 4, No. 1, 2002, p. 54-59.

Research output: Contribution to journalArticle

@article{ee39fe27d0b34cdcace921a8cf78399d,
title = "Eprosartan: An angiotensin-II receptor antagonist for the management of hypertension",
abstract = "Eprosartan is a competitive angiotensin-II receptor antagonist with a high affinity for the angiotensin-II subtype 1 receptor. The drug has an elimination half-life of approximately 5 to 9 hours and duration of antihypertensive effect of up to 24 hours. The antihypertensive efficacy of eprosartan has been examined in a number of placebo-controlled, dose-finding, and comparative trials. Results of these clinical trials have consistently shown statistically significant differences in antihypertensive efficacy favoring eprosartan doses of 400 mg or greater per day over placebo. Eprosartan was also shown to be at least as effective as enalapril at lowering blood pressure in patients with mild to severe hypertension. The frequency of adverse events observed with eprosartan has been similar to that seen with placebo. In addition, there are no clinically significant drug interactions associated with eprosartan. Given the excellent tolerability and drug-interaction profiles of eprosartan, the use of this agent may help to improve patient compliance to a drug regimen. In addition, eprosartan may be particularly advantageous when used as a part of combination therapy for the management of hypertension.",
author = "Angela Cheng-Lai",
year = "2002",
language = "English (US)",
volume = "4",
pages = "54--59",
journal = "Heart Disease",
issn = "1521-737X",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Eprosartan

T2 - An angiotensin-II receptor antagonist for the management of hypertension

AU - Cheng-Lai, Angela

PY - 2002

Y1 - 2002

N2 - Eprosartan is a competitive angiotensin-II receptor antagonist with a high affinity for the angiotensin-II subtype 1 receptor. The drug has an elimination half-life of approximately 5 to 9 hours and duration of antihypertensive effect of up to 24 hours. The antihypertensive efficacy of eprosartan has been examined in a number of placebo-controlled, dose-finding, and comparative trials. Results of these clinical trials have consistently shown statistically significant differences in antihypertensive efficacy favoring eprosartan doses of 400 mg or greater per day over placebo. Eprosartan was also shown to be at least as effective as enalapril at lowering blood pressure in patients with mild to severe hypertension. The frequency of adverse events observed with eprosartan has been similar to that seen with placebo. In addition, there are no clinically significant drug interactions associated with eprosartan. Given the excellent tolerability and drug-interaction profiles of eprosartan, the use of this agent may help to improve patient compliance to a drug regimen. In addition, eprosartan may be particularly advantageous when used as a part of combination therapy for the management of hypertension.

AB - Eprosartan is a competitive angiotensin-II receptor antagonist with a high affinity for the angiotensin-II subtype 1 receptor. The drug has an elimination half-life of approximately 5 to 9 hours and duration of antihypertensive effect of up to 24 hours. The antihypertensive efficacy of eprosartan has been examined in a number of placebo-controlled, dose-finding, and comparative trials. Results of these clinical trials have consistently shown statistically significant differences in antihypertensive efficacy favoring eprosartan doses of 400 mg or greater per day over placebo. Eprosartan was also shown to be at least as effective as enalapril at lowering blood pressure in patients with mild to severe hypertension. The frequency of adverse events observed with eprosartan has been similar to that seen with placebo. In addition, there are no clinically significant drug interactions associated with eprosartan. Given the excellent tolerability and drug-interaction profiles of eprosartan, the use of this agent may help to improve patient compliance to a drug regimen. In addition, eprosartan may be particularly advantageous when used as a part of combination therapy for the management of hypertension.

UR - http://www.scopus.com/inward/record.url?scp=0036270863&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036270863&partnerID=8YFLogxK

M3 - Article

C2 - 11975834

AN - SCOPUS:0036270863

VL - 4

SP - 54

EP - 59

JO - Heart Disease

JF - Heart Disease

SN - 1521-737X

IS - 1

ER -